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Background
BRAF G469A is a missense mutation within exon 11 of
the BRAF gene resulting in a constitutively active state
of the enzyme responsible also for the protein localiza-
tion to the mitochondria. The BRAF G469A mutation,
frequently recovers in lung cancer, is rare in melanoma
and uncertain is its association with a more aggressive
disease. BRAF G469A mutation is frequently associated
to MAP kinase cascade signaling activation, however no
evidence currently exists about its role in determining
sensitivity/resistance to BRAF inhibitors vemurafenib or
dabrafenib. In our Institute, a patient with metastatic
melanoma (MM) was treated with fotemustine, however
the disease progressed. From patient biopsy, a new
metastatic melanoma cell line has been established and
named Mo-1. Here, we investigated the sensitivity of
Mo-1 cells to vemurafenib and abraxane, both already
approved for the treatment of melanoma carrying BRAF
V600 mutations, comparing it with that found in MM
cells wild type for BRAF or mutated in V600. Further-
more, a biomarker for the response to abraxane is
hypothesized.
Materials and methods
We tested the sensitivity of Mo-1 (BRAF G469A), HBL
and LND-1 (BRAF wild type), MBA72 and Hmel-1
(BRAF V600) to abraxane and vemurafenib by MTT
cytotoxicity assay. In addition, cellular effectors were
investigated by ELISA kits, western blotting and flow
cytometry.
Results
The exposure to vemurafenib leads to a progressive
inhibition of proliferation however, the concentrations
utilized are high and similar to those utilized in MM
models constitutively resistant to BRAF inhibitors. Thus,
the BRAF mutation G469A confers resistance to vemur-
afenib also confirmed by the partial response obtained
when the patients was treated with the drug. The cellu-
lar effector responsible for the resistance might be the
activation of Erk1/2.
The binding of BRAF G469A to the outer mitochon-
drial membrane suggested to evaluate the mitochondria
functionality in Mo-1 cells. An high production of ATP
and the release of lactate were evident.
Finally, abraxane, which induces mitochondria-mediated
apoptosis, strongly reduced proliferation in Mo-1 cells.
Possible biomarker responsible for this response is the
very low expression level of PMEL17, transcriptionally
regulated by MITF, which is known to be negatively
involved in determining the activity of taxanes.
Conclusion
Thus, the mutation BRAF G469A in patients with MM
should be related to a weak effectiveness of therapy with
BRAF inhibitors and a promising therapeutic approach
may be with abraxane.
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